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Abstract
Background: Frozen shoulder (also known as adhesive capsulitis) occurs when the capsule, or the soft tissue envelope
around the ball and socket shoulder joint, becomes scarred and contracted, making the shoulder tight, painful and stiff.
It affects around 1 in 12 men and 1 in 10 women of working age. Although this condition can settle with time (typically
taking 1 to 3 years), for some people it causes severe symptoms and needs referral to hospital. Our aim is to evaluate the
clinical and cost-effectiveness of two invasive and costly surgical interventions that are commonly used in secondary care
in the National Health Service (NHS) compared with a non-surgical comparator of Early Structured Physiotherapy.
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Methods: We will conduct a randomised controlled trial (RCT) of 500 adult patients with a clinical diagnosis of frozen
shoulder, and who have radiographs that exclude other pathology. Early Structured Physiotherapy with an intra-articular
steroid injection will be compared with manipulation under anaesthesia with a steroid injection or arthroscopic (keyhole)
capsular release followed by manipulation. Both surgical interventions will be followed with a programme of
post-procedural physiotherapy. These treatments will be undertaken in NHS hospitals across the United Kingdom.
The primary outcome and endpoint will be the Oxford Shoulder Score (a patient self-reported assessment of
shoulder function) at 12 months. This will also be measured at baseline, 3 and 6 months after randomisation; and
on the day that treatment starts and 6 months later. Secondary outcomes include the Disabilities of Arm Shoulder and
Hand (QuickDASH) score, the EQ-5D-5 L score, pain, extent of recovery and complications. We will explore the
acceptability of the different treatments to patients and health care professionals using qualitative methods.
Discussion: The three treatments being compared are the most frequently used in secondary care in the
NHS, but there is uncertainty about which one works best and at what cost. UK FROST is a rigorously
designed and adequately powered study to inform clinical decisions for the treatment of this common
condition in adults.
Trial registration: International Standard Randomised Controlled Trial Register, ID: ISRCTN48804508. Registered
on 25 July 2014.
Keywords: Frozen shoulder, Physiotherapy, Manipulation under anaesthesia, Arthroscopic capsular release,
Randomised controlled trial
Background
A large, United Kingdom (UK)-based primary care study
found that ‘frozen shoulder’ affects 8.2% of men and
10.1% of women of working age [1]. A shoulder
surgeon’s hospital care experience in the UK, however,
suggests that the term frozen shoulder is often overused
and misused, with incidence in the general population
around 1% [2]. Although viewed as a self-limiting condi-
tion, long-term follow-up data are scarce [3]. Based on a
series of 233 patients with a mean follow-up of 4.4 years
from onset of symptoms, 59% had normal or near nor-
mal shoulders, 35% had mild-to-moderate symptoms
with pain being the most common complaint and 6%
had severe symptoms at follow-up [4]. Recent systematic
reviews have identified large gaps in the evidence-base
and uncertainty in the effectiveness of treatments for
frozen shoulder and a need for high-quality primary re-
search [5, 6]. From searching the Health Technology As-
sessment (HTA) website and the ISRCTN register, there
was no large-scale, multi-centre, randomised controlled
trial (RCT) of interventions for primary frozen shoulder
being undertaken.
The aim of our research is to provide evidence of
clinical and cost-effectiveness for commonly used inter-
ventions in the National Health Service (NHS) for the
management of frozen shoulder in secondary care. We
used the findings of a national survey of health care pro-
fessionals [7] to inform the decision to compare Early
Structured Physiotherapy (ESP) and intra-articular ster-
oid injection with the two most frequently used and
more costly surgical interventions, i.e. manipulation
under anaesthesia (MUA) and arthroscopic capsular
release (ACR). As evidence about patient experiences of
a frozen shoulder is limited [5], participants will be
interviewed to explore their experience and acceptability
of treatment 12 months after enrolment into the study
[8]. We will also interview health care professionals
about the acceptability of the trial treatments. The
objectives are listed in Table 1. The Standard Protocol
Table 1 UK FROST trial objectives
Objectives
1 The primary objective is to determine the effectiveness of ESP versus
MUA versus ACR for patients referred to secondary care for treatment
of primary frozen shoulder. This will be achieved using as a parallel-
group RCT and, as our primary outcome, the Oxford Shoulder Score
(OSS) which is a patient-reported outcome measure at 3, 6 and 12
months. The primary time point is 12 months after randomisation
2 To compare the cost-effectiveness of the three management policies,
to identify the most efficient provision of future care, and to describe
the resource impact that various policies for frozen shoulder manage
ment will have on the NHS
3 To qualitatively explore the acceptability of the different treatments
to patients and health care professionals and to provide important
patient-centred insight to further guide clinical decision-making
4 To update the HTA-funded systematic review of management of the
frozen shoulder for RCT evidence of the effectiveness of these inter
ventions in secondary care. This will allow our findings to be consid
ered in the context of existing evidence on all treatments of interest
for this condition
5 To use networks of health care professionals, patients, health service
managers and commissioning groups to widely disseminate the
findings of this study. This will be in addition to publishing the
results of the study in key journals and publishing the HTA report
ACR arthroscopic capsular release, ESP Early Structured Physiotherapy, HTA
Health Research Authority, MUA manipulation under anaesthesia
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Items Recommendations for Interventional Trials
(SPIRIT) Statement 2013 have been followed for the
completion of the protocol (see also Additional file 1:
SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents).
Methods
Trial design
UK FROST is a randomised, controlled, multi-centre
superiority trial comparing three parallel groups (ESP
versus MUA versus ACR) for patients referred to
secondary care for treatment of primary frozen shoulder.
The primary outcome and endpoint will be the Oxford
Shoulder Score at 12 months after enrolment into the
study. Computer-generated randomisation will be per-
formed using permuted blocks of random sizes, stratified
by the presence of diabetes, with unequal random alloca-
tion (1:2:2; ESP:MUA:ACR). To reduce the risk of alloca-
tion prediction we will not stratify by centre. We will
include a concomitant economic evaluation and a nested
qualitative study with trial participants and health care
professionals. An internal pilot study will confirm
feasibility.
Study setting
We estimated that we will need to recruit from 25 NHS
hospitals in the UK across a range of urban and rural
areas. The pragmatic design of the trial and wide
clinician involvement will ensure the applicability and
generalisability of study findings. Table 2 lists the
hospital sites that will be set up to recruit patients into
the trial.
Eligibility criteria
Patients with primary frozen shoulder will be identified
through clinical examination and plain radiographs [9].
The clinical examination will include the key diagnostic
assessment of restriction of passive external rotation in
the affected shoulder [10]. There is evidence of good
inter-rater agreement on whether restriction is present
[11] and a high threshold (50% restriction) for inclusion
should sufficiently minimise diagnostic uncertainty. Plain
radiographs (antero-posterior and axillary projections) of
the affected shoulder will be obtained routinely for all
patients to exclude glenohumeral arthritis and other
pathology that could lead to similar clinical presentation
(e.g. locked posterior dislocation). Table 3 presents the
eligibility criteria for participants.
The trial team will assess potential sites against
criteria (e.g. willingness to allocate treatment based
on randomisation, provision of all three treatments,
timeliness of delivering surgery etc.) for feasibility to
deliver the trial. A qualified physiotherapist (i.e. not a
student or assistant) will deliver the physiotherapy.
The participating surgeons will be familiar with the
surgical procedure(s). There will be no requirements
for the minimum number of these surgical procedures
that the surgeon needs to perform and no grade of
surgeon will be excluded. The participating site will
Table 2 UK FROST trial participating sites
Study sites
1 Aberdeen Royal Infirmary
2 Basildon and Thurrock University Hospitals NHS Foundation Trust
3 Bedford Hospital NHS Trust
4 Blackpool Teaching Hospitals NHS Foundation Trust
5 Cardiff and Vale University Health Board
6 Dorset County Hospital NHS Foundation Trust
7 Dudley Group NHS Foundation Trust
8 East and North Hertfordshire NHS Trust
9 East Kent Hospitals University NHS Foundation Trust
10 Forth Valley Royal Hospital
11 Frimley Health NHS Foundation Trust
12 Glasgow Royal Infirmary
13 Hampshire Hospitals NHS Foundation Trust
14 Maidstone and Tunbridge Wells NHS Trust
15 North Bristol NHS Trust
16 North Tees and Hartlepool NHS Foundation Trust
17 Northern Devon Healthcare NHS Trust
18 Northumbria Healthcare NHS Foundation Trust
19 Oxford University Hospitals NHS Trust
20 Perth Royal Infirmary
21 Robert Jones and Agnes Hunt Orthopaedic Hospital NHS
Foundation Trust
22 Royal Alexandra Hospital
23 Royal Free London NHS Foundation Trust
24 Royal Liverpool and Broadgreen University Hospitals NHS Trust
25 Sandwell and West Birmingham Hospitals NHS Trust
26 Sherwood Forest NHS Foundation Trust
27 South Tees Hospitals NHS Foundation Trust
28 Southport and Ormskirk NHS trust
29 Taunton and Somerset NHS Foundation Trust
30 The James Paget University Hospital NHS Foundation Trust
31 The Mid Yorkshire Hospitals NHS Trust
32 Torbay and South Devon NHS Foundation Trust
33 United Lincolnshire Hospitals NHS Trust
34 University Hospital Coventry and Warwickshire NHS Trust
35 University Hospital of South Manchester NHS Foundation Trust
36 University Hospitals of Leicester NHS Trust
37 University Hospitals of North Midlands NHS Trust
38 West Glasgow Ambulatory Care Hospital
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decide who can operate on patients and whether the
individual needs to be supervised by a consultant. We
will record the level of experience of physiotherapists
and surgeons who deliver the trial treatments in
terms of their grade and typical number of frozen
shoulder patients that they treat.
Interventions
The components and standardisation of the surgical trial
interventions were informed by a survey of 53 surgeons
who were principal investigators (PIs) for two multi-
centre shoulder surgery RCTs, i.e. PROFHER [12] and
UKUFF [13]. Notably, 28 of 35 (80%) responded that
they routinely use a steroid injection with MUA; 14 of
46 (30%) routinely provide steroid injection with ACR;
34 of 46 (74%) routinely perform MUA with ACR; and
13 of 46 (28%) and 8 of 46 (17%) surgeons, respectively,
routinely release the posterior capsule or perform a sub-
acromial decompression during ACR. The stand-alone
physiotherapy (ESP) and the post-procedural physiother-
apy programmes were developed using evidence from a
systematic review [5], UK guidelines [14], previous sur-
veys of UK physiotherapists [15, 16] and consensus from
expert shoulder physiotherapists in secondary care using
Delphi methodology [17]. Further details of the physio-
therapy programmes will be published separately.
Manipulation under anaesthesia with an intra-articular
steroid injection
Participants will be placed on the surgical waiting list
with routine pre-operative screening. In keeping with
NHS waiting list targets, the procedure will be per-
formed within 18 weeks of randomisation under a
general anaesthetic usually as a day case. The affected
shoulder is manipulated to stretch and tear the tight
capsule and to improve range of movement. Surgeons
will use an intra-articular injection of corticosteroid to
the glenohumeral joint whilst the patient is under the
same anaesthetic unless it is contraindicated. Post-
operative analgesia, including nerve blocks, will be pro-
vided as per usual care in the treating hospital. If the
MUA is incomplete, the surgeon will not cross over
intra-operatively to capsular release. The details of the
procedure will be collected prospectively using a Case
Report Form (CRF).
Arthroscopic capsular release with MUA
Participants will be placed on the surgical waiting list with
routine pre-operative screening for this procedure, which
will be performed within 18 weeks of randomisation under
a general anaesthetic, usually as a day case. Arthroscopic
release of the contracted rotator interval and anterior cap-
sule will be performed, followed by MUA to complete the
release of the inferior capsule. Surgeons will use at their
discretion additional procedures like posterior capsular
release and subacromial decompression. Supplementary
steroid injections, which slightly increase the risk of infec-
tion and morbidity, will also be used at the surgeon’s dis-
cretion [18]. Post-operative analgesia, including nerve
blocks, will be provided as per usual care. The details of
the procedure will be collected prospectively using a CRF.
Nested shoulder capsular tissue and blood samples study
At selected hospitals we will undertake an exploratory
nested capsular tissue and blood samples study with the
following objectives:
1. To determine molecular processes and cellular
abnormalities in tissue obtained during surgery
2. To determine serum protein and cytokine signatures
3. To correlate any tissue and serum abnormalities
detected with clinical presentation and response to
treatment
The nested study will include patients allocated to
ACR with MUA who have not received a steroid injec-
tion in the 6 weeks prior to their surgery. When the date
for surgery is known, the research nurse (RN) will post a
letter to the patient about the nested study, an informa-
tion leaflet and a consent form. The RN will seek to rec-
ord written informed consent when the patient attends
for their pre-surgery assessment. This is an exploratory
study, with no formal power calculation, and plans to
include 20 patients.
A tissue sample of capsule from the rotator interval,
which is routinely incised or removed as part of ACR,
Table 3 Patient eligibility criteria
Patients, including diabetics, are eligible for inclusion if they:
1. Are aged 18 years or older
2. Present with a clinical diagnosis of frozen shoulder characterised by
restriction of passive external rotation in the affected shoulder to less
than 50% of the contralateral shoulder
3. Have radiographs that exclude glenohumeral arthritis and other
pathology
Patients will be excluded from this study if:
1. They have a bilateral concurrent frozen shoulder
2. They have a frozen shoulder secondary to trauma, i.e. trauma to
the shoulder that required hospital care, e.g. fracture, dislocation,
rotator cuff tear
3. They have a frozen shoulder secondary to other causes, e.g. recent
breast surgery, radiotherapy
4. Any of the trial treatments are contraindicated, e.g. unfit for
anaesthesia or corticosteroid injection
5. They are not resident in a catchment area of a trial site
6. They lack mental capacity to understand the trial or instructions for
treatment
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will be obtained for analysis. A venous blood sample will
also be collected during surgery. The samples will be
fresh-frozen, stored on dry ice and transported securely
by courier to the University of Oxford Musculoskeletal
BioBank, housed at the Botnar Research Centre, where
formal analysis of the capsular tissue will take place.
Early Structured Physiotherapy with an intra-articular
steroid injection (comparator treatment)
Participants will receive up to 12 sessions of structured
physiotherapy over 12 weeks. This will comprise essen-
tial ‘focussed physiotherapy’ and optional ‘supplementary
physiotherapy’.
The ‘focussed physiotherapy’ package will include an
information leaflet containing education, advice on pain
management and function; an intra-articular steroid
injection and ‘hands-on’ mobilisation techniques—in-
creasingly stretching into the stiff part of the range of
movement as the condition improves—for which there
is reasonable evidence of effectiveness [19, 20]; and
instruction on a graduated home exercise programme
progressing from gentle pendular exercises to firm
stretching exercises according to stage, which is accepted
good practice. All participants randomised to ESP will
undergo all elements of this focussed physiotherapy
package unless there is a specific clinical reason for them
not to do so (e.g. steroid injection in a patient with
uncontrolled diabetes; or in a patient with a stiff, but
painless, non-irritable shoulder).
Supplementary physiotherapy will comprise those
interventions that are not essential, but which are
permissible additions, to allow physiotherapists some
flexibility. These interventions, which may have been
omitted from the national guidelines because they were
outside their scope (e.g. acupuncture), and/or because
there was a lack of primary academic literature (e.g.
hydrotherapy, soft-tissue release techniques), were
explored using a Delphi process.
Patients who do not improve with ESP will be referred
for further treatment in consultation with the treating
clinician at a 12-week assessment. When further treat-
ment after ESP involves surgical intervention, patients
will be placed on the normal surgical waiting list. Any
further treatment provided will be recorded. We will
reimburse the travel expenses for trial participants allo-
cated to ESP. A CRF will be used to record the ESP
given at each session (e.g. injection, advice and educa-
tion, gentle active exercise).
Post-procedural physiotherapy (PPP)
Following MUA or ACR, patients will undergo a
programme of physiotherapy of up to 12 weeks, normally
commencing within 24 h, with the aim of reducing pain
and regaining/maintaining the mobility achieved at
operation. This PPP is not intended to be identical to ESP
because it is applied in a very different context. The re-
search literature is uninformative, but we pre-specified
two ‘focussed physiotherapy’ interventions on the basis of
established good practice. These are provision of an infor-
mation leaflet containing education, advice on pain man-
agement and function; and instruction on a graduated
home exercise programme. All participants randomised to
MUA or ACR will undergo all elements of this focussed
physiotherapy package unless there is a specific clinical
reason for them not to do so. The interpretation of the
Delphi survey results was as for ESP. A steroid injection
will be avoided during PPP. A CRF will be used to record
the PPP given at each session.
Steroid injections
The steroid injections will be administered with or with-
out imaging guidance depending on the usual practice of
the hospital site as current evidence does not support
the superiority of either approach [21].
Modifications to interventions
There will be no explicit criteria for modification or
discontinuation of the assigned trial treatment. The
clinician and participant will discuss whether or not to
continue with a treatment for reasons such as poorly
controlled diabetes or the treatment no longer being
required.
Adherence to interventions
Adherence to the trial treatments will be explained in
the Trial Site Manual and Site Initiation Visits (SIVs). A
requirement of the internal pilot will be to check the
feasibility of delivering the ESP programme. This will be
extended to include the surgical interventions and PPP.
Every month a designated trial coordinator will extract
data from the hospital CRFs and update a spreadsheet to
record information about aspects of the treatments. The
chief investigator (CI), who is a consultant orthopaedic
surgeon, and the lead physiotherapist, will review the
spreadsheet for treatment adherence and decide whether
any action should be taken with a site. This will be fur-
ther monitored by the Trial Management Group (TMG),
the independent Trial Steering Committee (TSC) and
the Data Monitoring Ethics Committee (DMEC).
Concomitant care
Management of a patient waiting for surgery may include
analgesia to ensure pain relief, general advice on care of
the arm (e.g. axillary hygiene) and general advice to pre-
vent further stiffness in the limb. This will not include a
specific home exercise programme (like that provided
with the structured physiotherapy intervention); and a
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steroid injection will be avoided, as these are considered
active interventions.
Outcomes
Primary outcome (Oxford Shoulder Score)
Our primary outcome will be the Oxford Shoulder Score
(OSS), a patient-reported measure of functional limitation
following shoulder surgery. Development and validation
included patients with frozen shoulder [22] and it has
been used in the long-term follow-up of these patients [4].
The OSS is a 12-item measure with five response categor-
ies and a range of scores from 0 (worst) to 48 (best) [23].
It has been validated against the professionally endorsed
Constant Score [24] and the 36-item Short Form Health
Survey (SF-36) and responsiveness over a 6-month period
following surgical intervention has been established [25].
The OSS will be completed at the hospital at baseline (i.e.
day of randomisation) and posted to trial participants at 3,
6 and 12 months after randomisation. The primary end-
point is 12 months after randomisation. The OSS will also
be collected at the hospital on the day that treatment
starts (i.e. day of the operation or for patients allocated to
ESP on the day when the steroid injection is given or first
visit to physiotherapy, whichever is the first to be deliv-
ered) and posted to participants to complete 6 months
from when treatment starts. The OSS is being collected
on the day the treatment starts and 6 months later due to
the variation in waiting times as to when the trial inter-
ventions start.
Secondary outcomes
Secondary outcomes will be measured at baseline, 3, 6
and 12 months from randomisation unless otherwise
stated.
Quick Disabilities of Arm Shoulder and Hand
(QuickDASH) Comparative validity of functional limita-
tion measures is currently unclear for frozen shoulder. We
will, therefore, include a well-validated, condition-specific
measure for comparison with the OSS. The DASH (Dis-
abilities of the Arm, Shoulder and Hand) is one of the
most widely used, well-validated and reliable measures of
symptoms and functional limitation in the upper extrem-
ity [26]. To minimise responder burden we will use the
validated short version, the QuickDASH [27]. This 11-
item version is scored from 0 to 100 and endorsed by the
American Association of Orthopaedic Surgeons [27]. An
8-unit improvement in scores has been defined as the
minimum clinically important difference for patients with
shoulder problems [28]. Validity and responsiveness for
frozen shoulder has been established [29].
EuroQol 5 Dimensions (EQ-5D-5 L) The EQ-5D is a
validated, generic and health economic, self-completed,
patient-reported outcome measure covering five health
domains with three response options [30, 31]. The 5 L
version consists of the same five domains as the original
EQ-5D-3 L (mobility, self-care, usual activities, pain/dis-
comfort and anxiety/depression), but with five levels ra-
ther than three. This is to help overcome problems with
ceiling effects and to improve sensitivity [32, 33]. The
EQ-5D-3 L has been validated for a range of shoulder
conditions [34, 35]. The 5 L version will provide a simple
descriptive profile of health status that can be used to
estimate quality-adjusted-life-year (QALY) scores in
economic evaluations.
Pain Shoulder pain ‘during the past 24 h’ will be mea-
sured using the Numeric Rating Scale for pain [36], a
single 11-point numeric scale with 0 representing ‘no
pain’ and 10 representing ‘worst possible pain’, consid-
ered the most valid measure for this population [37].
Extent of recovery To inform the extent of resolution
of symptoms over time we will use a simple subjective
global question to assess the impact of participants’ fro-
zen shoulder symptoms in the past 24 h on their need
for treatment. Responses will be measured using a Visual
Analogue Scale from 0 to 100 with best-case (no need to
ask for treatment) and worst-case (definitely ask for
treatment) anchors.
Complications All complications will be recorded at 12
months for the past year. Infection will be defined as for
the ‘Surgical Site Infection’ audit [38]. Delayed wound
healing will be defined as any wound that has not healed
by 2 weeks. Complex regional pain syndrome will be de-
fined after surgery as pain, swelling and stiffness of the
shoulder that has been operated on, and arm and/or
hand restricting full tuck of the fingers. Additional com-
plications like nerve, blood vessel, tendon or bone injury;
complications related to steroid injection, including
steroid flare and septic arthritis, will be recorded.
Participant timeline
Figure 1, based on the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) Figure,
illustrates the overall schedule and time commitment for
trial participants from initial eligibility screening, time
periods during which trial treatments will be delivered
and the data collection/assessments to be performed.
Sample size
The primary outcome is the OSS. This will be assessed for
three treatment comparisons: ESP compared with MUA;
ESP compared with ACR (where for both of these com-
parisons we are testing for a 5-point mean difference on
the OSS); and MUA versus ACR (where we are testing for
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a 4-point mean difference). A 5-point improvement, with
a standard deviation (SD) of 12, can be found on the OSS
(standard effect size of 0.42) in shoulder patients treated
conservatively [39] and with complication-free surgery
(author AR, unpublished data, 2014). The developers of
the OSS agree that this improvement represents a min-
imal clinically important difference [23]. This larger effect
size will be required to justify the greater costs and poten-
tial risks associated with surgery. A smaller mean differ-
ence of 4 points on the OSS (standard effect size of 0.33)
is expected to distinguish between MUA and ACR. To ob-
serve the above effect sizes with 90% power and 5% two-
sided significance, adjusting for a conservative estimate (r
= 0.4) of the correlation between OSS over 12 months and
allowing for 20% attrition, a total sample size of 500 pa-
tients is required (ESP: 100; MUA: 200; ACR: 200). Owing
to the a priori specified sequence of treatment compari-
sons, multiplicity should not be a concern [40]. Thus, no
adjustments are made to the calculation.
Recruitment
For NHS hospitals in England in 2009/2010 and 2010/
2011, using Hospital Episode Statistics that exclude
post-trauma or secondary referral from other specialties,
there is a stable rate of 210 per million patients treated
for frozen shoulder. Assuming that 50% of frozen shoul-
der patients presenting in secondary care meet the inclu-
sion criteria and 40% consent (based on the PROFHER
trial experience comparing surgical versus conservative
care in shoulder fracture patients) that leaves around 40
patients per million to be recruited into the trial. To re-
cruit 500 trial participants from trusts that serve around
Fig. 1 Schedule of enrolment, interventions and assessments for the UK FROST trial. aPatients expected to receive allocated surgical procedure
within 18 weeks of randomisation followed by post-procedural physiotherapy. bPhysiotherapy logbooks completed recording delivery of Early
Structured Physiotherapy (ESP) and post-procedural physiotherapy. cThe primary outcome only will be collected on the day treatment starts, i.e.
on the day of the patient’s operation or, for patients allocated to ESP, on the day when the steroid injection is given or their first visit to physiotherapy,
whichever is the first to be delivered. It will then be collected again 6 months later. dReminders sent to sites upon return of physiotherapy logbooks
and at 1 year to confirm whether any (further) changes in patient status or adverse events need reporting
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a half-million catchment area we expect to need 25 hos-
pitals to recruit for a minimum of 1 year. This estimate,
however, requires no delays in set up or problems at any
time after that, all surgeons at a site to participate, and
all potential participants to be screened for eligibility.
Our experience is that it will be feasible to set up 25
hospitals; however, up to 30 months will be required to
meet our recruitment target.
To assess their feasibility to successfully recruit we will
ask sites to complete an Expression of Interest Form.
The study will be endorsed by the British Elbow and
Shoulder Society (BESS) and publicised at the annual
BESS conferences. The CI will approach PIs of previous
surgical trials of the shoulder (UKUFF and PROFHER)
to identify collaborating surgeons and the trial team will
also approach PIs at BESS conferences.
Two patients who had been treated for a frozen shoul-
der at the lead site (James Cook University Hospital) will
comment on the patient information leaflet and the con-
sent process for trial participation. The advice of an inde-
pendent patient representative member of the TSC will
also be sought. Following a qualitative study of patients
with frozen shoulder using semi-structured interviews
[41], we identified the need to develop a leaflet to provide
general information about what is a frozen shoulder.
Hospital staff, including an RN normally from the
National Institute for Health Research (NIHR) Clinical
Research Network, will be provided with training in
recruitment at the SIVs. A Trial Site Manual will be pre-
pared for hospital staff which will include guidance on
consenting patients into the trial and how to answer
questions that might arise during consent. In addition, a
poster will be provided to publicise the trial to hospital
staff and patients. During the trial, training and
reminders will be implemented using regular email bul-
letins and face-to-face meetings with PIs and RNs. Trial
coordinators will provide support and guidance to staff
when required.
Assignment of interventions
The RN or assessing clinician will identify patients who
have been referred for a frozen shoulder to an outpatient
hospital clinic. In the clinic, a designated individual within
the shoulder team (e.g. surgeon, physiotherapist) will
complete a CRF to confirm whether the patient is eligible
or not; and when applicable, approach the patient about
the study. The RN will then provide an information sheet
and answer any questions. The patient can agree to
consent at that time or take up to a week to decide.
When the patient does not consent, a further CRF will
be completed by the RN to briefly record the reason for
the patient not consenting and their treatment plan. The
patient will also be offered an optional CRF to complete
if they would like to provide more information about
why they did not take part.
When patients consent and complete their baseline
forms, the recruiting clinician will contact York Trials
Unit (YTU), either by telephone or via the Internet, to
access a secure, computer-generated randomisation
service. This will ensure treatment concealment and
unbiased allocation. Unequal random allocation (1:2:2 for
ESP:MUA:ACR) will be used to allow for the potential dif-
ference in effect between treatment comparisons, and
stratified by presence of diabetes which is significantly
associated with impaired shoulder motion in this patient
population [8]. The patient will be informed by the
clinician of their treatment allocation.
To ensure concealment we will not stratify by centre
and use permuted blocks of random sizes. The random-
isation service will record information and check patient
eligibility to avoid inappropriate entry of patients into
the trial. Patients and the hospital staff will be informed
of the allocation. The study office in York will send an
allocation letter to the patient explaining what will hap-
pen next. The participant’s general practitioner will also
receive a letter about treatment allocation. As the trial is
pragmatic in design, comparing surgical and non-
surgical treatment options, the blinding of participants
and clinicians to treatment allocation is not possible.
Data collection methods
Postal questionnaires will be used to collect data com-
pleted by trial participants as already described. In
addition, paper CRFs will be used to record all the infor-
mation required from the protocol that will be collected
from the hospital. Each trial participant will have a unique
four-digit identification number that will be pre-recorded
on all CRFs. There will be an instructions page at the start
of each postal questionnaire and for the more complex
hospital CRFs. At the SIV we will provide advice on
completion of the CRFs including a Trial Site Manual for
hospital staff. Active and systematic follow-up of all ran-
domised participants by post will include pre-notification
reminders, 2- and 4-week letter reminders and the option
to complete an abridged questionnaire (a minimum of the
OSS and EQ-5D) via telephone after 6 weeks. At 12
months, the primary time point, we will include an uncon-
ditional incentive of £5 [42]. Text messages will be sent on
the day that the participant is sent the postal question-
naire [43] and newsletters will be circulated to trial partici-
pants [44]. A central database at YTU will manage data
collection. A trial participant can entirely withdraw from
the study at any time for any reason but any data collected
up to that point will be included in the analysis. The
participant can also agree to being withdrawn from only
postal questionnaire collection or only hospital CRF
collection.
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Data management
The patient questionnaires and hospital CRFs will be de-
signed using TeleForm software (version 10; Cardiff Soft-
ware, Cambridge, UK) and marked up with variable names
and appropriate scoring. To maximise data quality, when
hospital CRFs are returned to YTU, key variables required
for the statistical analysis, and checking adherence in the
delivery of the treatments will be reviewed for completion
and accuracy by a research data administrator, who will re-
solve any queries with the RN at the site. The hospital site
will be reimbursed for the completion of CRFs which will
be signed off by the trust and trial sponsor using a Clinical
Trial Agreement. No checks regarding data quality of the
postal questionnaires will be made on immediate return to
YTU. A trial coordinator will, however, as a duty of care,
check whether the participant has responded to the last
EQ-5D-5 L question that ‘I am extremely anxious and de-
pressed’ and check free-text responses to questions on
whether the participant could be at risk of harm. When
this occurs, the PI, RN and CI will be notified by email.
After this initial check, all postal questionnaires and hos-
pital CRFs will pass through a process of scanning in the
Teleform software, second checking and validation against
predetermined rules.
Essential trial documentation will be kept with the
Trial Master File and Investigator Site Files. The sponsor
will ensure that this documentation is retained for a
minimum of 5 years after the conclusion of the trial.
The postal questionnaires and hospital CRFs will be
stored for a minimum of 5 years after the conclusion of
the trial as paper records; and a minimum of 20 years in
electronic format [45].
Statistical methods
The flow of participants through each stage of the trial
will be presented in a Consolidated Standards of Report-
ing Trials (CONSORT) diagram [46]. Unadjusted OSS
will be summarised descriptively (n, mean, SD, median,
minimum and maximum) at each time point by treat-
ment group and overall. To inform treatment selection
we will determine (1) whether the two surgical interven-
tions are significantly superior to ESP, and if so, (2)
whether key-hole surgery is superior to MUA. Three
comparisons will be carried out: ACR versus ESP, MUA
versus ESP and ACR versus MUA. All analyses will be
carried out using two-sided significance tests at the 0.05
significance level.
Our primary analysis will compare the treatment groups
at 12 months. For each of the three treatment compari-
sons, the primary outcome OSS will be analysed using a
linear mixed model, including assessments at all available
time points with reference to the date of randomisation (3,
6 and 12 months, thereby increasing power) and treating
patients as a random effect. The model will adjust for OSS
at baseline and include as fixed effects: treatment arm,
time, arm by time interaction and covariates for age,
gender and whether diabetic. The model will provide
treatment-group differences over 12 months as well as
estimates at individual time points. These will be presented
as mean estimates with 95% confidence intervals and asso-
ciated p values.. For the modelling of repeated measure-
ments, the best fitting (based on AIC and BIC information
criteria), simple (not significantly different from an un-
structured pattern) covariance pattern will be selected.
Any missing data will be assumed to be missing at ran-
dom. Model assumptions will be checked and, if they are
in doubt, the data will be transformed prior to analysis or
alternative non-parametric analysis methods will be used.
The primary analysis will be conducted as intention-
to-treat (ITT), including patients in the groups to which
they were randomised. To take account of the effects of
an expected degree of cross-over, secondary analyses will
be carried out using Complier Average Causal Effect
analysis at the 12-month time point which retains the
initial randomised assignments, thus overcoming the
problems of per-protocol analysis [47]. A separate sec-
ondary ITT model will include the baseline OSS, OSS
on the day treatment starts and OSS 6 months later with
the same covariates as the primary analysis to inform
the influence of variable treatment waiting times on the
results of the study.
Two separate exploratory sub-group analyses will be
undertaken: differences in treatment response according
to whether the patient has diabetes (yes or no) and
whether the patient had received physiotherapy for their
affected shoulder prior to enrolment into the trial (yes or
no). Simple descriptives of the primary outcome will be
reported for the sub-groups. A treatment group by sub-
group interaction term will be included in the primary
analysis model for each sub-group analysis. For each sub-
group analysis, the estimated treatment by sub-group
means with associated confidence intervals will be
reported along with the p value for the interaction term.
To explore the potential effect of patients’ knowledge
of which treatment they received (allocation cannot be
blinded) and their experience of this treatment on the
results of the trial as measured by the primary outcome,
we will take two approaches. First, eligible patients will
be asked at baseline if they have any treatment prefer-
ence (physiotherapy, no preference or surgery; and if
surgery, which type) and their expectations of the effect-
iveness of each treatment. These preferences and expec-
tations will be descriptively explored by trial arm as well
as for compliant and crossover patients. Separate sec-
ondary analyses of the ITT primary outcome model will
be conducted including an interaction of the randomised
treatment with: treatment preferences, preference rating
of the allocated treatment, effectiveness expectations of
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each treatment and effectiveness rating of the allocated
treatment. In addition, at the end of the 12-month
follow-up period, patients will again be asked to indicate
their treatment preference in the event of a similar
shoulder problem given their experience over the past
12 months. Patient preferences at 12 months’ follow-up
will be tabulated against baseline preferences and against
the allocated treatment. Second, it is possible that pa-
tients’ knowledge and experience of treatment may
result in non-response at follow-up. A logistic regression
model will be used to identify predictors of non-
response and will include all baseline data and primary
outcome assessments before any missing values. If any
variables are found to be predictive of non-response they
will be included in the model specified for the primary
analysis.
All unadjusted secondary outcomes will be reported
descriptively (mean, SD, median, minimum and max-
imum for continuous data and counts and percentages
for categorical data). The following outcomes will be
analysed using the same ITT methods as the primary
analysis adjusting for the same covariates: QuickDASH,
pain question and extent of recovery (assessed by a ‘need
for further treatment’ rating scale). Separate logistic
regression models will be used to determine treatment-
group differences in having experienced at least one
complication or adverse event.
Cost-effectiveness analysis
The economic evaluation will determine the relative
cost-effectiveness of three interventions for the treat-
ment of frozen shoulder. A cost-utility analysis will com-
pare the incremental health outcome, measured in terms
of QALYs, with the incremental cost among the three
treatment options. Costs and QALYs will be evaluated
from the perspective of the NHS and Personal Social
Services, consistent with that used by the National Insti-
tute for Health and Clinical Excellence [48].
Health-related quality of life will be assessed during
the trial period using the EQ-5D-5 L instrument. The
EQ-5D profiles generated for each patient will be valued
using a set of estimated preferences based on the UK
population that will be generated by the EuroQoL group
during the period of the trial [49]. The summary of the
EQ-5D utility scores at each follow-up point by each
treatment arm will be presented and the overall differ-
ence in utilities between the arms will be examined
through an appropriate model. QALYs will be estimated
using the area-under-the-curve analysis [50].
Health care resource data will be collected at different
time points using patient self-administered question-
naires and hospital CRFs and compared with the rele-
vant Health Resource Group. Cost per patient will be
estimated by multiplying the use of resource use by their
associated unit costs. Unit costs will be sourced from
the NHS Reference Costs databases [51], the Personal
Social Services Research Unit [52], the British National
Formulary [53] and other published literature. Though
the primary perspective of the cost analysis will be that
of the NHS and Personal Social Services, data on indir-
ect costs associated with patient private expenses, days
lost from work and from normal activities (e.g. house-
hold chores, shopping) will also be collected and in-
cluded in a secondary analysis.
Cost and QALY data will be synthesised to generate
an incremental cost-effectiveness ratio, which is defined
as the ratio of the mean difference in costs to the mean
difference in QALYs between treatments. Multivariate
regression models will be used to assess the heterogen-
eity in costs, QALYs and cost-effectiveness. Multiple im-
putation techniques will be used to address the
statistical issues related to the presence of missing data
in the economic evaluation [54]. In order to characterise
the uncertainty in the data, structural, scenario and
probabilistic sensitivity analyses will be conducted. The
uncertainty will be presented using a cost-effectiveness
acceptability curve which shows the probability of the
surgical interventions being more cost-effective than
ESP conditional on a maximum value being attached to
an additional unit of health outcome [55].
For the longer term, and if it is appropriate, QALYs for
each patient will be calculated by extrapolating results of
the trial-based analysis to a longer time horizon. For ex-
ample, by assessing the long-term impact on health-related
quality of life and costs at 5 years as at this time around
40% of patients continue to have from mild-to-severe
symptoms [4]. The potential value of further research in
this area will be considered [56].
Nested qualitative study
The trial will be supplemented by a qualitative study that
will focus on the following objectives to complement the
trial objectives: to explore the experience and acceptabil-
ity of the different treatments to patients and health care
professionals; and to provide important patient-centred
insight to further guide clinical decision-making. We will
also explore, as a subsidiary aim, participants’ experi-
ences of taking part in a surgical trial.
Up to 45 of the trial participants will take part in the
interviews and will be drawn from those who have experi-
enced the three trial treatments. As gender and diabetes
can have an impact on outcome from shoulder surgery [8]
effort will be made to include interviews with both men
and women, and those with and without diabetes. The in-
terviews will take place at approximately 12 months after
enrolment into the trial to mirror the primary time point
in the analysis. Interviews will be semi-structured with
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open questions. A flexible interview schedule will be devel-
oped following a literature review, discussions with the
research team, patients with frozen shoulder, a physiother-
apist and surgeon with expertise in this area. Interviews
will be open and flexible to allow participants the oppor-
tunity to introduce new topics, and generate a detailed,
personal perspective upon the topic [57]. We will continue
to interview men and women to a point of theoretical sat-
uration [58]; in short, until no further useful conceptual
categories emerge.
Interviews will be ideally undertaken face-to-face
although, given the geographic spread of participants, it
may be more practical to perform some interviews by tele-
phone or face-time interviews on-line (e.g. Skype); it is
expected that up to 50% of interviews will be performed
in this way. Interviews will be conducted by a qualitative
researcher and audio-recorded with permission; and
recordings will be transcribed in full.
We will also interview 10 to 15 health care profes-
sionals (physiotherapists and surgeons) about their
experience of delivering the treatment. An interview
schedule will be developed to address areas such as: clin-
ical decision-making; treatment preference; and barriers
to, and facilitators of, positive outcome of treatments.
To reflect the exploratory nature of this study, and
to ensure that the participants’ perspective is at the
heart of any insight generated, data analysis will be
undertaken inductively [59]. However, our analytic ap-
proach is underpinned by constructivism, which takes
the stance that qualitative research findings are not
‘discovered’ but co-constructed by the researcher and
participant [58]. Qualitative finding are thus an inter-
pretation. Through a process of constantly comparing
data [58], we will develop initial tentative conceptual
categories and then further abstract these categories
into overarching themes that will help us to under-
stand the experience. We will use NVivo qualitative
data analysis software version 11 to assist our organ-
isation of qualitative analysis. All interviews will be
analysed by the researcher conducting the interviews
with a second qualitative researcher coding a subset
of interviews and commenting on the development of
conceptual categories. The aim of this is not to reach
consensus but to challenge the emerging interpret-
ation and ensure interpretive rigour [60]. We will
develop our conceptual categories and themes collab-
oratively in team meetings.
Update of systematic review
To place the RCT findings in the context of current evi-
dence at the end of the trial, we will update the HTA
systematic review about the management of frozen
shoulder incorporating the proposed RCT and any other
new RCTs completed since the original searches were
undertaken [5]. The review protocol will be registered
on an international prospective register of systematic re-
view (PROSPERO) prior to the analysis of the trial being
undertaken. We will update the results of the review in-
corporating UK FROST and any other new RCTs. Any
differences between the updated and original review will
be highlighted.
Monitoring
Data monitoring
A DMEC, independent of the funding body, sponsor and
trial team, will be established and follow the research
governance guidelines provided by the funding body and
a charter. Only the DMEC will have access to the un-
blinded comparative data from the trial. The DMEC will
monitor the data and make any recommendations about
(dis)continuation of the trial to the independent TSC.
The TSC will meet after the DMEC and provide overall
supervision of the trial on behalf of the sponsor and
funder.
There are no planned interim analyses for the trial or
stopping guidelines. There will, however, be an internal
pilot study from which the data will contribute to the
final analyses. The primary reason for this pilot study is
for the DMEC and TSC to check the assumptions about
the feasibility of the trial to continue as planned or not,
particularly concerning participant adherence to the ESP
and intra-articular steroid injection.
Adverse event management
Adverse events are any untoward medical occurrence in
a trial participant and may be a non-serious adverse
event (AE) or a serious adverse event (SAE). At partici-
pating sites, all SAEs will be recorded and returned to
the ‘UK FROST’ central office within 24 h of the investi-
gator becoming aware of them. Once received, causality
and expectedness will be determined by the CI. SAEs
that are unexpected and related to the trial will be noti-
fied to Research Ethics Committee (REC) within 15 days
for a non-life threatening event and within 7 days for a
life-threatening event. For non-serious AEs, the central
office will be notified within 5 days of the event being
known. All (S)AEs will be reported to the DMEC, TSC
and TMG. Expected adverse events for this shoulder
condition include: infection; bleeding; delayed wound
healing; conversion of planned day-case procedure to
overnight stay for control of pain; post-procedural wors-
ening of shoulder pain; injury to adjacent structures like
nerve, tendon, bone or joint; recurrent stiffness requir-
ing further treatment; and transient hyperglycaemia,
steroid flare or joint sepsis following corticosteroid injec-
tion; injuries related to heating or cooling of tissues.
Follow-up reports a month later will be reviewed by the
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CI to ensure that adequate action has been taken and
progress made. We will only record (S)AEs that are re-
lated to the affected shoulder up to 12 months from
randomisation.
Auditing
South Tees Hospitals NHS Foundation Trust will be the
sponsor for this project. This study will be fully compli-
ant with the Research Governance Framework and Good
Research Practice [45]. The TMG will review core trial
processes/progress on a quarterly basis which includes
representation from the sponsor. No site visits to moni-
tor progress are planned but could be initiated depend-
ing on progress made as reviewed at the TMG.
Ethics and dissemination
Research Ethics Committee approval
REC approval was granted on 18 November 2014 (NRES
Committee North East – Newcastle and North Tyneside
2). Health Research Authority (HRA) approval for the
study with an existing UK wide review was granted on
15 June 2016.
Protocol amendments
Any substantial amendments will be submitted to the
REC having been agreed with: the funding body, sponsor,
TSC, DMEC, TMG and the Research Governance Com-
mittee for the Department of Health Sciences, University
of York. Minor modifications to the protocol will be
agreed with the TMG and sponsor before submission for
approval to REC. All amendments will be implemented
in the NHS organisations in agreement with the guid-
ance and approval of the HRA. All amendments will be
listed in the published final report to the funding body.
Consent or assent
Written consent will be obtained for all trial participants
by the trained local RN or clinician using a detailed
patient information sheet developed with the help of ser-
vice users and explaining the risks and benefits clearly.
For the nested qualitative study we will write to the trial
participants and health care professionals about taking
part in the interviews and to confirm this with written
consent. Information sheets will again be provided.
Confidentiality
All data will be identified by a coded ID (identification)
number to maintain participant confidentiality. All
study-related paper forms will be stored securely in the
University of York and, after a period of time, trans-
ferred to a secure, off-site facility below ground with no
moisture, no vermin and virtually no fire risk. Access to
the archive area is via a security controlled mine shaft
with no outward markings to advertise its presence. All
electronic records will be stored on a password-
protected server and will be anonymous of identifiable
information. All participant information will be stored in
locked cabinets in areas with restricted access (i.e.
alarmed area) at the University of York. For the qualita-
tive interviews, recordings and transcripts will be kept
anonymised and kept in a locked office at the University
of Oxford. Any quotation that could clearly be used to
identify a person will not be used in the dissemination of
findings. Participants’ data may be reviewed by
authorised persons on the research team or other
authorised people to verify that the study is being carried
out correctly all of whom will have a duty of confidenti-
ality. Trial participants will consent on enrolment to per-
mit this authorised review. All names and other
identifying information will be removed before the data
is analysed and the results presented to the medical
community at conferences and in scientific journals.
Declaration of interests
The independent members of the DMEC and TSC will
sign a form to confirm that they have no competing in-
terests to declare. Competing interests of the authors are
presented at the end of the protocol.
Access to data
The Secretary of State for Health (the Authority) has the
right to access data during the research and will respect
existing guidance on confidentiality for any data which it
obtains. Data that will be shared internally within the
trial team will be blinded of any identifying participant
information to ensure confidentiality. When there is a
request to use UK FROST data from external re-
searchers this will be notified to the TMG. When the
TMG agrees to an external request for data the approval
for this will be confirmed with the sponsor and the
funding body. Data will be provided in an anonymised
format and securely transferred to the requester.
Ancillary and post-trial care
The trial treatments are all routinely available in the
NHS. Therefore, any ancillary care of post-trial care that
includes continuing treatment of a frozen shoulder
should be accessible to all trial participants in discussion
with their clinician. If a trial participant wishes to com-
plain formally, they will be advised to do this through
the usual NHS Complaints Procedure. If a patient is
harmed and this is due to someone’s negligence then
they may have grounds for legal action or compensation
against the sponsor (in respect of harm arising out of
participation in the trial) or the NHS (in respect of any
harm which has resulted from the treatment received).
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Dissemination policy
The trial results will be disseminated regardless of the
magnitude or direction of effect [61] to key stakeholders
and patients in several ways: peer-reviewed journal in-
cluding the HTA monograph; to Commissioning Refer-
ence Groups; presented at key scientific meetings; made
available on specialist websites; feedback to trial partici-
pants, update the entry on Wikipedia and write the Map
of Medicine entry on frozen shoulder management;
through press releases at collaborating universities; and
we will explore non-academic routes to dissemination
such as patient.co.uk.
The criteria for authorship will be taken from the Inter-
national Committee of Medical Journal Editors [62]. Those
who do not meet the authorship criteria but contributed
to aspects of the study design or drafting of work will be
acknowledged as contributors. Those who were solely in-
volved in trial conduct (e.g. staff at recruiting sites) will be
acknowledged as collaborators. When a journal permits
we will list all authors rather than use a group name.
This protocol is being made publicly available. The full
trial report will be submitted to the funding body and for
publication in a peer-reviewed journal. The full trial report
will be open access and made available as a permanent
archive in the NIHR Journals Library. At the time of pub-
lishing the protocol there was no plan to make the anon-
ymised participant-level dataset and statistical code for
generating the results publicly available. After publication
of the main trial findings, however, an external request
that is made for this data and code will be agreed by the
TMG and confirmed with the sponsor and funding body.
Discussion
This research will further knowledge and understand-
ing of the impact of frozen shoulder on the clinical
and cost-effectiveness of physiotherapy and the more
invasive surgical treatments commonly used. There is
increasing awareness that the findings from RCTs are
more valuable when considered in the context of
existing evidence on all treatments of interest. There-
fore, we will update the recent HTA systematic re-
view about the management of the frozen shoulder
[5] but with a focus on RCTs of the interventions in-
cluded in the trial. Contextualising our research find-
ings in this way will help inform clinical practice in
the NHS and provide direction for future research in
this area.
Trial status
The current REC approved version of the protocol is ver-
sion 4.0 (15 November 2016). This manuscript is a re-
structured and edited version of the current REC-
approved protocol to comply with the SPIRIT guidelines.
The first patient was recruited into the trial on 14 April
2015 and recruitment should be complete for the end of
December 2017.
Additional file
Additional file 1: The Standard Protocol Items Recommendations for
Interventional Trials (SPIRIT) Statement 2013 have been followed for the
completion of the protocol (see also Additional file 1: SPIRIT 2013
Checklist: recommended items to address in a clinical trial protocol and
related documents). (DOC 120 kb)
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